Acurx Pharmaceuticals Inc... (ACXP)
| Bid | 0.35 |
| Market Cap | 8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.83B |
| EPS (ttm) | -0.87 |
| PE Ratio (ttm) | -0.41 |
| Forward PE | -0.38 |
| Analyst | Buy |
| Ask | 0.36 |
| Volume | 99,185 |
| Avg. Volume (20D) | 284,122 |
| Open | 0.35 |
| Previous Close | 0.34 |
| Day's Range | 0.35 - 0.36 |
| 52-Week Range | 0.30 - 3.33 |
| Beta | -1.35 |
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bac...
Analyst Forecast
According to 1 analyst ratings, the average rating for ACXP stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 3261.34% from the latest price.
Stock Forecasts
3 weeks ago · seekingalpha.com
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call TranscriptAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President...